1 Time to diagnosis of AF was the primary
outcome measure.
2 sions reduced loss adaptation in the primary
outcome measure.
3 on with total volume of distribution (VT) as
outcome measure.
4 ation of microglial activation as an imaging
outcome measure.
5 e presence or absence of SCT was the primary
outcome measure.
6 ucleatum were analyzed for prediction of the
outcome measure.
7 xycholesterol levels in serum as the primary
outcome measure.
8 observed treatment effects on any behavioral
outcome measure.
9 re used to analyze the longitudinal repeated
outcome measures.
10 h the clinician-administered and self-report
outcome measures.
11 created to estimate odds ratios for the main
outcome measures.
12 mory, and processing speed) were the primary
outcome measures.
13 ects of levothyroxine were seen on secondary-
outcome measures.
14 (n = 10) reported no significant changes in
outcome measures.
15 amplitude change predicted post-hoc learning
outcome measures.
16 ly important differences (MID) were the main
outcome measures.
17 results, as measured by objective functional
outcome measures.
18 e found similar results in several secondary
outcome measures.
19 an difference 0.006, -0.009 to 0.02; p=0.42)
outcome measures.
20 , and health-related quality-of-life (HRQoL)
outcome measures.
21 disease and vascular dementia were secondary
outcome measures.
22 ysical and mental health, medication and BMI
outcome measures.
23 del) maximized performance across a range of
outcome measures.
24 Four criteria are proposed to assess
outcome measures.
25 GD) and correlate these data with functional
outcome measures.
26 SF can provide greater precision than scalar
outcome measures.
27 spectral domain optical coherence tomography
outcomes measured.
28 etest control that did not complete the main
outcome measures;
16 participants provided no state-chan
29 of questionnaires as patient/person-reported
outcome measures;
3) describe prescribed medications, or
30 ild development is related to adult economic
outcomes measured 30 y later.
31 Of interest, although not defined as
outcome measures a priori, the KGF group, compared with
32 bidity, which has meanwhile reached standard
outcome measures accepted for major liver surgery.
33 t tests were used to identify differences in
outcome measures after the institution of reforms.
34 The primary
outcome, measured after listening to the entire podcast,
35 25 mm Hg in both studies (ROCKET-2, primary
outcome measure and population, ROCKET-1, post hoc outco
36 ical activity, heterogeneity between dietary
outcome measures and a paucity of evidence around harmfu
37 ty instruments, including patient-orientated
outcome measures and objective signs (Eczema Area and Se
38 At month 6, 348 participants (96%) had VA
outcomes measured and 335 participants (93%) had spectra
39 Incident all-cause dementia was the main
outcome measure,
and single- and dual-task gait velocity
40 dy characteristics, patients, interventions,
outcome measures,
and results at short- and long-term fo
41 is (CF) indicates that sensitive noninvasive
outcome measures are needed for diagnostic monitoring an
42 Patient-reported
outcome measures are problematic, because low response r
43 Primary safety
outcome measures are the incidence of study product-rela
44 each statistical significance for predicting
outcome measured as a continuous variable (p = 0.07) for
45 Primary end points were patient-reported
outcome measures as assessed by the validated BREAST-Q s
46 Morbidity rate has become an important
outcome measure,
as the mortality rates of most surgical
47 Main
outcome measures assessed every 6 mo included the total-
48 were administered the A-IQOLS, other asthma
outcome measures (
Asthma Control Test, Asthma Symptom Ut
49 The main secondary
outcome measure at 1 year follow-up was disability, meas
50 f 779 patients provided data for the primary
outcome measure at baseline and at least 1 follow-up.
51 baseline and every 4 weeks, with the primary
outcome measured at 6 months.
52 y of maternal-infant attachment was the main
outcome measured at infant age 18 mo.
53 3 days post injury strongly correlates with
outcome measures at 12 weeks post injury.
54 ipants enrolled, 139 (94%) completed primary
outcome measures at 3 months and 133 (90%) completed sec
55 Outcome measures at 3 months, 6 months, and 9 months pos
56 between self-harm during adolescence and the
outcome measures at 35 years (wave 10) using logistic re
57 t 3 months and 133 (90%) completed secondary
outcome measures at 9 months; multiple imputation was us
58 The
outcome measures at age 35 years were social disadvantag
59 s for 2 years after the surgery; the primary
outcomes, measured at 1 year and 2 years, were participa
60 he identification of potential biomarkers of
outcome measures,
availability of relevant animal models
61 Outcome Measures:
Average lifetime costs, life-years, an
62 gnosed at younger than 20 years, with single
outcome measures between 2011 and 2015.
63 ns were found between MMI score and practice
outcomes measured by mentor grading.
64 Functional
outcomes measured by the absolute value and the variatio
65 te significant heterogeneity in exposure and
outcome measures,
clear evidence shows that the burden o
66 and CHALICE in predicting each rule-specific
outcome measure (
clinically important traumatic brain in
67 the Clinical Outcomes in Routine Evaluation
Outcome Measure (
CORE-OM), with higher scores indicating
68 d for a national dialogue about how to judge
outcome measures currently in use or proposed for the fu
69 These criteria were applied to 10
outcome measures currently used or proposed for accounta
70 art of treatment to "presumed cure" (primary
outcome measure,
defined as a closed epithelial defect w
71 Outcome measures defining the impact of globalization on
72 NTERPRETATION: These data of SMA and control
outcome measures delineates meaningful change in clinica
73 function was found to be a suitable primary
outcome measure for a future trial; adjusted mean differ
74 clinical evaluation and has usefulness as an
outcome measure for future retinal intervention studies.
75 g 1 year, BCVA is unlikely to be a sensitive
outcome measure for STGD1 treatment trials with 1 year's
76 estigation of disease pathogenesis and as an
outcome measure for therapeutic interventions.
77 ing that incidence of DDAF could serve as an
outcome measure for treatment trials.
78 To determine
outcome measures for a clinical trial of Leber congenita
79 These variables would be potential anatomic
outcome measures for CHM clinical trials and could be st
80 ay help outline the eligibility criteria and
outcome measures for clinical trials for CHM.
81 Sensitive
outcome measures for clinical trials on cerebellar ataxi
82 Our main
outcome measures for comparison between groups were (1)
83 Sensitive
outcome measures for disease progression are needed for
84 A comprehensive set of
outcome measures for liver diseases is not currently ava
85 ich to date have relied solely on functional
outcome measures for patient enrollment, stratification,
86 No difference was found in
outcome measures for patients with AF and age- and sex-m
87 of overlapping phenotypes that may serve as
outcome measures for preclinical studies of PTHS treatme
88 hospital and ICU lengths of stay (LOS) were
outcome measures for severity.
89 The primary
outcome measures for the study were coverage of OPV, IPV
90 nt next step toward developing a set of core
outcome measures for this field of research.
91 New
outcome measures for treatment trials for Stargardt dise
92 Outcome Measures:
HIV transmissions and deaths, years of
93 ve and positive biopsies were similar in the
outcome measures;
however, positive-biopsy patients were
94 Survival analysis represents an important
outcome measure in clinical research and clinical trials
95 This could be used as a sensitive anatomic
outcome measure in clinical trials related to STGD.
96 of retinal function and will be an important
outcome measure in future clinical trials.
97 tions in the Subpopulations and Intermediate
Outcome Measures in COPD Study (SPIROMICS) cohort, we an
98 nts from the Subpopulations and Intermediate
Outcome Measures in COPD Study (SPIROMICS) using questio
99 e SPIROMICS (Subpopulations and Intermediate
Outcome Measures in COPD Study) cohort.
100 aled stronger positive associations for most
outcome measures in males and at doses below the current
101 The
Outcome Measures in Rheumatology comprehensive conceptua
102 g emphasis on incorporating patient-reported
outcome measures in routine care for patients with heart
103 s to identify and delineate relevant patient
outcomes measured in studies that reported nursing inter
104 e SPIROMICS (Subpopulations and Intermediate
Outcomes Measures in COPD Study) (n = 1,544) and COPDGen
105 Secondary
outcome measures include IOP, glaucoma medical therapy,
106 Main
outcome measures include proportion of eye care provider
107 Secondary
outcome measures included 30-day postoperative complicat
108 Outcome measures included AL, corneal curvature, and the
109 Outcome measures included C. difficile test utilization,
110 Primary
outcome measures included change in proteinuria and chan
111 Secondary
outcome measures included changes in pulse wave velocity
112 calibrated and blinded examiners; secondary
outcome measures included decayed, missing, or filled te
113 Outcome measures included densitometry data in 4 corneal
114 Our
outcome measures included differences in RNFL thickness
115 Additional prespecified secondary
outcome measures included health-related quality of life
116 Main
outcome measures included incidence rates of vision loss
117 Secondary
outcome measures included induction of labor, low birth
118 Prespecified
outcome measures included low-grade CIN (grade 1 [CIN1])
119 Secondary
outcome measures included mean change in visual acuity (
120 Main
outcome measures included participant's decision to acce
121 Main
outcome measures included rates of visual loss and ocula
122 Outcome measures included reduction in intraocular press
123 Main
outcome measures included safety (rate of treatment-rela
124 Outcome measures included scores on neuropsychological m
125 Main
outcome measures included serious morbidity, in-hospital
126 Secondary
outcome measures included surgical feasibility, visual a
127 Secondary
outcome measures included the number of charges submitte
128 Patient-reported
outcome measures included the scores on the Physical Com
129 Secondary
outcome measures included the time until onset of pain a
130 Secondary
outcome measures included time to tumor progression, pro
131 Outcome measures included total distance traveled and ra
132 Outcome Measures:
Incremental costs, quality-adjusted li
133 riance in cognitive performance and clinical
outcome measures,
independent of the associated antecede
134 riance in cognitive performance and clinical
outcome measures,
independently and jointly.
135 of improvement in study design, selection of
outcome measures,
interpretation of results, and the ove
136 Main
outcome measure is consistency of ophthalmic outcomes me
137 The primary
outcome measure is the rate of surgical failure, defined
138 et longitudinally collected patient-reported
outcome measures is unknown.
139 omography angiography, we assessed 3 primary
outcome measures:
left ventricular (LV) systolic functio
140 OUTCOME MEASURES:
lowest observed adverse effect levels
141 An additional 56 prespecified
outcomes measured maternal health-care use, content of c
142 OUTCOME MEASURES:
MNRead maximum reading speed, sustaine
143 Fourth, implementation of the
outcome measure must have little chance of inducing unin
144 were identified comprising patient reported
outcome measures (
n=31), and biologic measures and repor
145 OUTCOME MEASURE:
Odds ratios (OR) were calculated for gl
146 INTERPRETATION: Using the CMTPedS as an
outcome measure of disease severity, children with CMT p
147 ripheral biomarker candidate as an objective
outcome measure of target engagement for clinical trials
148 Outcome measures of brain metabolism, neuroinflammation,
149 ween lanicemine and placebo treatment on any
outcome measures related to MDD.
150 observe significant differences in multiple
outcome measures related to the affective sphere of pain
151 tically significant improvements on multiple
outcome measures related to the affective sphere of pain
152 We also extracted
outcome measures relevant to DR and asked respondents to
153 outcome measure is consistency of ophthalmic
outcomes measures reported.
154 nd secondary endpoints, and patient-reported
outcome measures,
reported in the methods and results se
155 MAIN
OUTCOME MEASURE(
S): At 3 months postoperatively, UCVA an
156 An
outcome measure should be used only if the outcome can b
157 Hence, there is a strong need for sensitive
outcome measures such as disease and progression biomark
158 similar effects on several of the secondary
outcome measures,
such as the PANSS negative symptom, to
159 nagement decisions, the absence of a uniform
outcome measure that represents visual or aesthetic sequ
160 Outcome measures that are sensitive to disease progressi
161 ied, and reported, a set of multidimensional
outcome measures that are sensitive to nursing intervent
162 ific HRQoL instruments because there are few
outcome measures that are validated and reliable in pati
163 Outcome measures that reflect the entire cycle of care a
164 nce from placebo was detected on the primary
outcome measure,
the parent-rated Aberrant Behavior Chec
165 MAIN
OUTCOMES MEASURES:
The primary objective was to show non
166 found no effect of simvastatin on the other
outcome measures,
these potential effects warrant confir
167 We present a list of
outcome measures to enable the pooling and comparison of
168 ibing the natural history, and ultimately as
outcome measures to evaluate therapies.
169 A standardized set of patient-centered
outcome measures to inform value-based health care in co
170 PRIMARY
OUTCOME MEASURE:
Uncorrected (UCDVA) and best-corrected
171 Primary
outcome measures varied across the trials analysed: two
172 Outcome measures varied from study to study and included
173 nge from baseline to month 24 on the primary
outcome measure was 0.18 for olesoxime and -1.82 for pla
174 The primary
outcome measure was 30-day ERI.
175 The primary
outcome measure was 5-year overall survival.
176 The primary
outcome measure was a three-level outcome - survival wit
177 The primary
outcome measure was all-cause mortality rate at 2 weeks
178 The primary
outcome measure was all-cause mortality within 30 days o
179 The primary
outcome measure was all-cause mortality.
180 The primary
outcome measure was anterior chamber cell grades at day
181 Our main
outcome measure was change from month 6 to month 12 in v
182 The main
outcome measure was change in amblyopic eye VA from base
183 The primary
outcome measure was change in antimicrobial prescription
184 The primary
outcome measure was change in BMI over 5 years.
185 The main
outcome measure was change in infection rates from basel
186 The primary
outcome measure was change in score on the Montgomery-As
187 The primary
outcome measure was change in sickness absence among tho
188 The primary
outcome measure was child weight loss (body mass index [
189 The primary
outcome measure was clinical event rates, measured from
190 The primary
outcome measure was conversion from caries-free to carie
191 The primary
outcome measure was conversion from caries-free to carie
192 on revascularisation) and the primary safety
outcome measure was definite or probable device thrombos
193 The primary
outcome measure was development of >/=1 SAE; secondary o
194 The primary
outcome measure was device retention at 24 and 60 months
195 Main
outcome measure was final anatomic status.
196 Our main
outcome measure was fractional anisotropy (FA), a measur
197 Primary
outcome measure was hazard ratio (HR) of failure, with f
198 The
outcome measure was improvement in probing depth of >/=2
199 The primary
outcome measure was in-hospital mortality.
200 The main
outcome measure was in-hospital mortality.
201 Primary
outcome measure was incidence and severity of systemic a
202 Primary
outcome measure was intraocular pressure (IOP) reduction
203 The primary
outcome measure was late toxicity.
204 The primary
outcome measure was methyl aminolevulinate-induced PPIX
205 The primary
outcome measure was net health benefit (NHB), which was
206 The primary
outcome measure was overall survival (defined as the dif
207 The primary
outcome measure was overall survival, and primary and sa
208 The primary
outcome measure was overall survival.
209 The primary
outcome measure was overall survival; short-term periope
210 The main
outcome measure was prediction error at 7 years of age.
211 The main
outcome measure was SLT success (defined as IOP </= targ
212 The primary
outcome measure was speech comprehension score on the co
213 The primary
outcome measure was SSI score 24 hours after infusion (a
214 The primary
outcome measure was the Alzheimer's Disease Cooperative
215 Main
outcome measure was the annual incidence and prevalence
216 The primary
outcome measure was the area under the curve (AUC) of cu
217 The
outcome measure was the binding potential (BPND), using
218 The primary
outcome measure was the change in 6-minute walk distance
219 The primary
outcome measure was the change in the 17-item Hamilton D
220 The primary
outcome measure was the change in the Epworth Sleepiness
221 The primary
outcome measure was the change in the preoperative visua
222 The
outcome measure was the concordance between the percenta
223 The primary efficacy
outcome measure was the device-oriented composite endpoi
224 The main
outcome measure was the diagnosis of macular edema withi
225 Primary
outcome measure was the difference in change in central-
226 Based on a previous report, the primary
outcome measure was the effect of intra-epoch time (i.e.
227 A secondary
outcome measure was the effect of the site of the primar
228 The primary
outcome measure was the frequency of AEs.
229 The secondary
outcome measure was the impact of postoperative prophyla
230 The primary
outcome measure was the negative predictive value (NPV)
231 The main
outcome measure was the odds of discharge within 6 hours
232 The primary
outcome measure was the PANSS negative factor score (pen
233 The primary
outcome measure was the percentage of families stopping
234 Primary
outcome measure was the proportion of patients with a st
235 The primary
outcome measure was the rate of recurrent biliary events
236 Main
outcome measure was the retention of the capsular bag.
237 The primary
outcome measure was the shift in the degree of disabilit
238 The primary
outcome measure was the shift in the degree of disabilit
239 The primary
outcome measure was to characterize the clinical feature
240 The main
outcome measure was vision-related functional burden, wh
241 The
outcome measure was VT/fP (VT is volume of distribution
242 The primary
outcome measured was the postoperative early and late co
243 e measure and population, ROCKET-1, post hoc
outcome measure).
was also noninferior to timolol (ROCKE
244 nitive impairment or dementia) at 2 years as
outcome measures,
we assessed the predictive values of b
245 Other
outcome measures were also not different between groups.
246 Main
outcome measures were asthma-related hospitalizations (6
247 Outcome measures were audibility, scores from the speech
248 The main
outcome measures were baseline NEI VFQ-25 composite and
249 Our main
outcome measures were best spectacle-corrected visual ac
250 Finally, simplified
outcome measures were calculated as ratio, with referenc
251 Main
outcome measures were changes from central gaze in the c
252 The primary
outcome measures were clinicopathological characteristic
253 Other
outcome measures were corrected distance visual acuity (
254 asure was development of >/=1 SAE; secondary
outcome measures were death, arteriothrombotic events, e
255 The primary
outcome measures were depression (measured by the PHQ-2
256 The main
outcome measures were diabetes (fasting plasma glucose >
257 The primary
outcome measures were diagnostic accuracy, sensitivity,
258 Two composite primary
outcome measures were evaluated: (i) CVD events/deaths (
259 The primary
outcome measures were for insomnia, paranoia, and halluc
260 Secondary
outcome measures were functional outcome, health-related
261 Main
outcome measures were hazard ratios (HRs) for post-surge
262 Outcome measures were implant and FPD failures, biologic
263 Outcome measures were improvement of discrimination by a
264 The main
outcome measures were incidence of graft infection, micr
265 Main
outcome measures were incidence or progression of DME or
266 Outcome measures were incremental cost-effectiveness rat
267 The primary
outcome measures were IOP reduction and the success rate
268 The primary
outcome measures were levels of plasma metabolites in pa
269 Primary
outcome measures were mean change in (1) tear osmolarity
270 Main
outcome measures were mean IAIs given through month 12 (
271 The main
outcome measures were mortality and unfavourable functio
272 Secondary
outcome measures were number of decayed, missing, or fil
273 ents, the CMT neuropathy score and secondary
outcome measures were obtained and a skin biopsy collect
274 The primary
outcome measures were overall mortality and cancer-speci
275 Secondary
outcome measures were PANSS total score and scores on th
276 Outcome measures were plaque index (PI), gingival index
277 The primary
outcome measures were positive donor rim fungal culture
278 The main
outcome measures were postoperative best-corrected visua
279 The main
outcome measures were postoperative surgical outcomes an
280 Secondary
outcome measures were PPIX photobleaching and clinical l
281 The main
outcome measures were risk of postpartum AD, duration of
282 Main
outcome measures were spending by Medicare as tracked by
283 The primary
outcome measures were the Evaluation du Vecu de l'Anesth
284 Main
outcome measures were the incidence of elevated IOP and
285 Main
outcome measures were the incidences of HIT-specific com
286 Primary
outcome measures were the mean and median CMS payments t
287 Outcome measures were the observed rate of corneal chang
288 The primary
outcome measures were the postintervention changes in fu
289 Primary
outcome measures were the prevalence of diagnosed ocular
290 The main
outcome measures were the proportion of children develop
291 Primary
outcome measures were the Rating for Premenstrual Tensio
292 The primary
outcome measures were the suicide items from clinician-a
293 Main
outcome measures were time to distant failure, local fai
294 Outcome measures were type I collagen crosslinked beta C
295 The main
outcome measures were: total number of drops, volume per
296 The
outcomes measured were health-care costs accrued in the
297 udies (n = 36) reported one or more positive
outcome measures,
whereas 22% of studies (n = 10) report
298 autoregulation index that predicted patient
outcome measured with the Glasgow Outcome Scale as a con
299 ete disability]) at 6 months was the primary
outcome measure,
with a minimal clinically important dif
300 h FC, PPT was more effective than SMC on all
outcomes measured,
with the exception of findings from t